Fig. 5

Combination of c-Met inhibitor with AZD4547 induced cell death of AZD4547-resistant cells overexpressing c-Met. (A) To determine the pathway signature activity, Gene Set Enrichment Analysis (GSEA) was performed in AZD4547-resistant and -sensitive patient-derived cells. (B) Expression of p-c-Met and c-Met was analyzed by western blotting in EOC cells. (C) Cell viability was measured in cells treated with SU11274, a c-Met-specific inhibitor, AZD4547, and the combination of SU11274 with AZD4547 in HayA8-MDR and SKOV3-TR cells for 48 h (*p < 0.05, **p < 0.001). (D) Expression of p-c-Met and c-Met was analyzed by western blot in lysates from the same experimental conditions as in (C). Expression of p-c-Met was normalized by total c-Met expression using Image J, and the result is shown in the right panel